


AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A sulfonamide compound of general formula (Ia)



(Ia)

wherein

R¹ represents an -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least mono-substituted, cycloaliphatic radical, which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member,

R², R³, R⁴, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical or an optionally at least mono-substituted phenyl radical or an optionally at least mono-substituted heteroaryl radical,

R⁵ represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

with the proviso that R⁸ and R⁹ are not hydrogen at the same time, and if one of them, R⁸ and R⁹, represents a saturated or unsaturated, linear or branched, optionally at least mono-

substituted C₁-C₄ aliphatic radical, the other one represents a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical with at least five carbon atoms, or

R⁸ and R⁹ together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted heterocyclic ring, which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted, mono- or bicyclic cycloaliphatic ring system which may optionally contain at least one heteroatom as a ring member,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and


n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, ~~preferably enantiomers or diastereomers~~, its racemate or in form of a mixture of at least two of its stereoisomers, ~~preferably enantiomers or diastereomers~~, in any mixing ratio, or a salt thereof, ~~preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.~~

Claim 2 (Currently Amended): A compound according to claim 1, ~~characterized in that~~ wherein R¹ represents an -NR⁸R⁹ radical or a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered cycloaliphatic radical which may optionally contain at least one heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring

system, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system are 5- or 6-membered;

preferably R^1 represents an NR^8R^9 radical or a radical chosen from the group consisting of



wherein, if present, the dotted line is an optional chemical bond, and R^{10} represents hydrogen, a linear or branched C_1 - C_6 alkyl radical or a benzyl radical, preferably hydrogen or a C_1 - C_2 alkyl radical.

Claim 3 (Currently Amended): A compound according to claim 1, characterized in that wherein R^2 , R^3 , R^4 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical;

preferably R^2 , R^3 , R^4 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,

more preferably R^2 , R^3 , R^4 , R^6 and R^7 each represent hydrogen or C_{1-2} alkyl.

Claim 4 (Currently Amended): A compound according to claim 1, wherein ~~one or more of claims 1, characterized in that~~ R^5 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical;

~~preferably R^5 represents hydrogen or a linear or branched, optionally at least mono-substituted C_4 - C_6 alkyl radical,~~

~~more preferably R^5 represents hydrogen or a C_4 - C_2 alkyl radical.~~


Claim 5 (Currently Amended): A compound according to claim 1, ~~characterized in that~~ wherein R^8 and R^9 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_{10} alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkenyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_{10} alkynyl radical,

or

R^8 and R^9 together with the bridging nitrogen atom form a saturated or unsaturated, optionally at least mono-substituted 5- or 6-membered heterocyclic ring which may contain at least one additional heteroatom as a ring member and/or which may be condensed with a saturated or unsaturated, optionally at least mono-substituted mono- or bicyclic cycloaliphatic ring system, which may optionally contain at least one heteroatom as a ring member, whereby the rings of the ring system ~~are 5-6- or 7-membered~~ are 5, 6- or 7-membered.

Claim 6 (Currently Amended): A compound according to claim 5, ~~characterized in that~~ wherein R^8 and R^9 , identical or different, each represent hydrogen or a linear or branched

C₁-C₁₀ alkyl radical, or R⁸ and R⁹ together with the bridging nitrogen atom form a radical chosen from the group consisting of




wherein R¹¹, if present, represents hydrogen, a linear or branched C₁-C₆ alkyl radical or a benzyl radical, preferably hydrogen, or a C₁-C₂ alkyl radical.

Claim 7 (Currently Amended): A compound according to claim 1, ~~characterized in that~~ wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via an optionally at least mono-substituted C₁-C₆ alkylene group, an optionally at least mono-substituted C₂-C₆ alkenylene group or an optionally at least mono-substituted C₂-C₆ alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring member;

~~preferably A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom;~~

~~or a radical chosen from the group consisting of~~



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, acetyl, linear or branched C₁-C₆-alkyl, linear or branched C₁-C₆-alkoxy, linear or branched C₁-C₆-alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆-alkyl,

W represents a single chemical bond between the two rings, a CH₂, O, S group or a NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆-alkyl,

m is 0, 1, 2, 3 or 4 and


m₁ is 1 or 2.

Claim 8 (Currently Amended): A compound according to claim 1 chosen from the group consisting of

- [16] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-2-sulfonamide,
- [17] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide,
- [18] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [28] N-[1-(2-pyrrolidine-1-yl-ethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- [43] 5-chloro-3-methyl-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzo[b]thiophene-2-sulfonamide,
- [44] N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-2-sulfonamide,
- [45] N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-1-sulfonamide,
- [46] 6-chloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide,
- [47] 4-phenyl-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonamide,
- [48] 2-(naphth-1-yl)-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)ethanesulfonamide,
- [49] 4-phenoxy-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonamide,
- [50] 3,5-dichloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)benzenesulfonylamide,
- [51] 4,5-dichloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)thiophene-2-sulfonamide and

[52] 5-chloro-N-(1-(3-(piperidin-1-yl)propyl)-1H-indol-5-yl)naphthalene-1-sulfonamide,
~~optionally in form of and~~ their corresponding salts ~~or their corresponding solvates.~~

Claim 9 (Currently Amended): A sulfonamide compound of general formula (Ib)



(Ib)

wherein

R¹ represents a -NR⁸R⁹ radical,

R², R³, R⁴, R⁶ and R⁷, identical or different, each represent hydrogen, halogen, nitro, alkoxy, cyano, a saturated or unsaturated, optionally at least mono-substituted, linear or branched aliphatic radical, or an optionally at least mono-substituted phenyl or an optionally at least mono-substituted heteroaryl radical,

R⁵ represents hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted aliphatic radical,

R⁸ and R⁹, identical or different, each represent hydrogen or a saturated or unsaturated, linear or branched, optionally at least mono-substituted, C₁-C₄ aliphatic radical,

A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, which may be bonded via an optionally at least mono-substituted alkylene, alkenylene or alkynylene group and/or which may contain at least one heteroatom as a ring member in one or more of its rings,

and n is 0, 1, 2, 3 or 4;

optionally in form of one of its stereoisomers, ~~preferably enantiomers or diastereomers~~, its racemate or in form of a mixture of at least two of its stereoisomers, ~~preferably enantiomers or diastereomers~~, in any mixing ratio, or a salt thereof, ~~preferably a corresponding, physiologically acceptable salt thereof, or a corresponding solvate thereof.~~

Claim 10 (Currently Amended): A compound according to claim 9, ~~characterized in that~~ wherein R^2 , R^3 , R^4 , R^6 and R^7 , identical or different, each represent hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical, or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical;

~~preferably R^2 , R^3 , R^4 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, more preferably R^2 , R^3 , R^4 , R^6 and R^7 each represent hydrogen or a C_{1-2} alkyl radical.~~

Claim 11 (Currently Amended): A compound according to claim 9, ~~characterized in that~~ wherein R^5 represents hydrogen, a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical, a linear or branched, optionally at least mono-substituted C_2 - C_6 alkenyl radical or a linear or branched, optionally at least mono-substituted C_2 - C_6 alkynyl radical;

~~preferably R^5 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical,~~

~~more preferably R^5 represents hydrogen or a C_1 - C_2 alkyl radical.~~

Claim 12 (Currently Amended): A compound according to claim 9 ~~characterized in~~
~~that~~ wherein R^8 and R^9 , identical or different, each represent hydrogen or a linear or
branched, optionally at least mono-substituted C_1 - C_4 alkyl radical,


~~preferably R^8 and R^9 , identical or different, each represent hydrogen or a C_1 - C_2 alkyl~~
~~radical,~~

with the proviso that R^8 and R^9 are not hydrogen at the same time.

Claim 13 (Currently Amended) A compound according to claim 9 ~~characterized in~~
~~that~~ wherein A represents an optionally at least mono-substituted mono- or polycyclic
aromatic ring system, wherein the ring(s) is/are 5- or 6-membered, which may be bonded via
an optionally at least mono-substituted C_1 - C_6 alkylene group, an optionally at least mono-
substituted C_2 - C_6 alkenylene group or an optionally at least mono-substituted C_2 - C_6
alkynylene group and/or wherein the ring(s) may contain at least one heteroatom as a ring
member;

~~preferably A represents an optionally at least mono-substituted mono- or polycyclic~~
~~aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more~~
~~of the rings contain at least one heteroatom,~~

~~or a radical chosen from the group consisting of~~



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, acetyl, linear or branched C₁-C₆-alkyl, linear or branched C₁-C₆-alkoxy, linear or branched C₁-C₆-alkylthio, a trifluoromethyl radical, a cyano radical and a -NR¹²R¹³ radical,

wherein R¹² and R¹³, identical or different, each represent hydrogen or linear or branched C₁-C₆-alkyl,

W represents a single chemical bond between the two rings, a CH₂, O, S group or a -NR¹⁴ radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆-alkyl,

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

Claim 14 (Currently Amended): A compound according to ~~claim 1~~ claim 9 selected from the group consisting of

- [1] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [2] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-2-sulfonamide,
- [3] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-naphthalene-1-sulfonamide,
- [4] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chloronaphthalene-1-sulfonamide,
- [5] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-benzenesulfonamide,
- [6] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-quinoline-8-sulfonamide,
- [7] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-phenoxybenzenesulfonamide,
- [8] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-methylbenzenesulfonamide,
- [9] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-5-chlorothiophene-2-sulfonamide,
- [10] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-benzo[1,2,5]thiadiazole-4-sulfonamide,
- [11] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- [12] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3,5-dichlorobenzenesulfonamide,
- [13] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3-bromobenzenesulfonamide,
- [14] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-3-nitrobenzenesulfonamide,
- [15] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-1-phenylmethanesulfonamide,

- [19] trans-N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-2-phenylethanesulfonamide,
- [20] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4,5-dichlorothiophene-2-sulfonamide,
- [21] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-acetylbenzenesulfonamide,
- [22] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-bromobenzenesulfonamide,
- [23] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-methoxybenzenesulfonamide,
- [24] ~~N-[3-(2-diethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide~~ N-[1-(2-diethylaminoethyl)-1H-indole-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulfonamide,
- [25] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-nitrobenzenesulfonamide,
- [26] N-[1-(2-dimethylaminoethyl)-1H-indole-5-yl]-4-fluorobenzenesulfonamide,
- [27] N-[1-(2-diethylaminoethyl)-1H-indole-5-yl]-6-chloroimidazo[2,1-b]thiazole-5-sulfonamide,
- [29] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-naphthalene-2-sulfonamide,
- [30] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-naphthalene-1-sulfonamide,
- [31] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)-4-phenylbenzenesulfonamide,
- [32] 5-chloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-3-methylbenzo[b]thiophene-2-sulfonamide,
- [33] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-naphthalene-2-sulfonamide,
- [34] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-naphthalene-1-sulfonamide,

- [35] 6-chloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)imidazo[2,1-b]thiazole-5-sulfonamide,
- [36] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-4-phenylbenzenesulfonamide,
- [37] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-2-(naphth-1-yl)-ethanesulfonamide,
- [38] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-4-phenoxybenzenesulfonamide,
- [39] 3,5-dichloro-N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)-benzenesulfonamide,
- [40] N-(1-(2-(dimethylamino)ethyl)-2-methyl-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide,
- [41] N-(1-(2-(diethylamino)ethyl)-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide
and
- [42] N-(1-(2-(dimethylamino)ethyl)-1H-indol-5-yl)benzo[b]thiophene-3-sulfonamide,
- ~~optionally in form of~~ and their corresponding salts ~~and their corresponding solvates.~~

Claims 15 - 17 (Canceled):

Claim 18 (Currently Amended): A ~~medicament~~ pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 1 and optionally at least one or more of pharmacologically acceptable excipients.

Claim 19 (Currently Amended): A ~~medicament~~ pharmaceutical composition according to claim 18, for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, ~~preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight,~~ for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), ~~preferably type II diabetes caused by obesity,~~ for the prophylaxis and/or treatment of gastrointestinal tract disorders, ~~preferably irritable bowel syndrome,~~ for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, ~~preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis,~~ schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder),

~~preferably for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), preferably type II diabetes caused by obesity, for the prophylaxis and/or treatment of gastrointestinal tract disorders, preferably irritable bowel syndrome.~~

Claims 20 - 45 (Canceled):

Claim 46 (Currently Amended): A ~~medicament~~ pharmaceutical composition comprising a therapeutically effective amount of at least one compound according to claim 9 and optionally at least one or more of pharmacologically acceptable excipients.


Claim 47 (Currently Amended): A ~~medicament~~ pharmaceutical composition according to claim 46 for 5-HT₆ receptor regulation, for the prophylaxis and/or treatment of a disorder or disease related to food intake, ~~preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight,~~ for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or type II diabetes (non insulin dependent diabetes mellitus), ~~preferably type II diabetes caused by obesity,~~ for the prophylaxis and/or treatment of gastrointestinal tract disorders, ~~preferably irritable bowel syndrome,~~ for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, ~~preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis,~~ schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder), ~~preferably for cognitive enhancement, for the prophylaxis and/or treatment of disorders of the central nervous system, anxiety, panic disorders, depression, bipolar disorders, cognitive memory disorders, senile dementia processes, neurodegenerative disorders, preferably Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis, schizophrenia, psychosis or infantile hyperkinesia (ADHD, attention deficit/hyperactivity disorder).~~

Claims 48 - 73 (Canceled):

Claim 74 (New): The compound according to claim 1, wherein the compound is in the form of a physiologically acceptable salt thereof.

Claim 75 (New): the compound according to claim 1, wherein the compound is in the form of its enantiomers or diastereomers or in the form of a mixture of at least two of its enantiomers and/or diastereomers.

Claim 76 (New): The compound according to claim 2, wherein R^1 represents an $-NR^8R^9$ radical or a radical chosen from the group consisting of



wherein, if present, the dotted line is an optional chemical bond, and R^{10} represents hydrogen, a linear or branched C_1-C_6 alkyl radical or a benzyl radical.

Claim 77 (New): The compound according to claim 76, wherein R^{10} is hydrogen or a C_1-C_2 alkyl radical.

Claim 78 (New): The compound according to claim 3, wherein R^2 , R^3 , R^4 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1-C_6 alkyl radical.


Claim 79 (New): The compound according to claim 78, wherein R^2 , R^3 , R^4 , R^6 and R^7 each represent hydrogen or a C_1 - C_2 alkyl.

Claim 80 (New): The compound according to claim 4, wherein R^5 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical.

Claim 81 (New): The compound according to claim 80, wherein R^5 represents hydrogen or a C_1 - C_2 alkyl radical.

Claim 82 (New): The compound according to claim 6, wherein R^{11} represents hydrogen or a C_1 - C_2 alkyl radical.

Claim 83 (New): The compound according to claim 7, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom, or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, acetyl, linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or branched C_1 - C_6 alkylthio, a trifluoromethyl radical, a cyano radical and a $-NR^{12}R^{13}$ radical,

wherein R^{12} and R^{13} , identical or different, each represent hydrogen or linear or branched C_1 - C_6 alkyl,

W represents a single chemical bond between the two rings, a CH_2 , O, S group or a NR^{14} radical,

wherein R^{14} is hydrogen or a linear or branched C_1 - C_6 alkyl,

m is 0, 1, 2, 3 or 4 and

m_1 is 1 or 2.

Claim 84 (New): The compound according to claim 9, wherein the salt is in the form of a physiologically acceptable salt thereof.

Claim 85 (New): The compound according to claim 9, wherein the compound is in the form of its enantiomers or diastereomers, or in the form of a mixture of at least two of its enantiomers and/or diastereomers.

Claim 86 (New): The compound according to claim 10, wherein R^2 , R^3 , R^4 , R^6 and R^7 , identical or different, each represent hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical.

Claim 87 (New): The compound according to claim 86, wherein R^2 , R^3 , R^4 , R^6 and R^7 each represent hydrogen or a C_1 - C_2 alkyl.


Claim 88 (New): The compound according to claim 11, wherein R^5 represents hydrogen or a linear or branched, optionally at least mono-substituted C_1 - C_6 alkyl radical.

Claim 89 (New): The compound according to claim 88, wherein R^5 represents hydrogen or a C_1 - C_2 alkyl radical.

Claim 90 (New): The compound according to claim 12, wherein R^8 and R^9 , identical or different, each represent hydrogen or a C_1 - C_2 alkyl radical.

Claim 91 (New): The compound according to claim 13, wherein A represents an optionally at least mono-substituted mono- or polycyclic aromatic ring system, wherein the ring(s) is/are 5- or 6-membered and wherein one or more of the rings contain at least one heteroatom,

or a radical chosen from the group consisting of



wherein X, Y, Z, independently from one another, each represent a radical selected from the group consisting of hydrogen, fluorine, chlorine, bromine, nitro, acetyl, linear or branched C_1 - C_6 alkyl, linear or branched C_1 - C_6 alkoxy, linear or branched C_1 - C_6 alkylthio, a trifluoromethyl radical, a cyano radical and a $-NR^{12}R^{13}$ radical,

wherein R^{12} and R^{13} , identical or different, each represent hydrogen or linear or branched C_1 - C_6 alkyl,

W represents a single chemical bond between the two rings, a CH_2 , O, S group or a NR^{14} radical,

wherein R¹⁴ is hydrogen or a linear or branched C₁-C₆ alkyl,

m is 0, 1, 2, 3 or 4 and

m1 is 1 or 2.

Claim 92 (New): A pharmaceutical composition according to claim 19, wherein the disorder or disease related to food intake is selected from the group consisting of regulation of appetite, the maintenance, increase or reduction of body weight; the type II diabetes is selected from type II diabetes caused by obesity; the gastrointestinal tract disorder is irritable bowel syndrome; and the neurodegenerative disorders are selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis.

Claim 93 (New): A pharmaceutical composition according to claim 47, wherein the disorder or disease related to food intake is selected from the group consisting of regulation of appetite, the maintenance, increase or reduction of body weight; the type II diabetes is selected from type II diabetes caused by obesity; the gastrointestinal tract disorder is irritable bowel syndrome; and the neurodegenerative disorders are selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease and/or multiple sclerosis.